2028 Marketing Pharmacokinetics Virus 
Drug Discovery World
AUGUST 10, 2022
By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. Exactly three decades later, the first CAR T cell therapy hit the market. Finally, ddPCR assays revealed that at low MOIs, centrifuging the cell/virus mixture increased copy number per cell.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. An update on Pfizer’s potential first-in-class maternal vaccine candidate for the prevention of respiratory syncytial virus (RSVpreF). BNT162 mRNA-based Vaccine Program. for RSV A and 18.0
Expert insights. Personalized for you.
246 
Let's personalize your content